Company record · updated October 7, 2026
Aerovate Therapeutics Inc: 5 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs October 31, 2024 to November 30, 2024.
5observations
5source filings
5verified rows
2024-11-30most recent as-of date
Source rails for this company: N-PORT fund mark (5).
Reported by 5 filers: Fidelity Advisor Biotechnology Fund, Fidelity Advisor Health Care Fund, Fidelity Small Cap Growth Fund, Fidelity Small Cap Growth K6 Fund, Select Health Care Portfolio.
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2024-11-30 | price per share | 5.56 USD | Select Health Care Portfolio | VERIFIED | valUSD 2915830.8 / balance 524430.0 [unspecified] | 000175272425015317 |
| 2024-10-31 | price per share | 4.949 USD | Fidelity Small Cap Growth K6 Fund | VERIFIED | valUSD 1145949.17 / balance 231554.0 [unspecified] | 000175272424297793 |
| 2024-10-31 | price per share | 4.9489 USD | Fidelity Small Cap Growth Fund | VERIFIED | valUSD 2732414.27 / balance 552120.0 [unspecified] | 000175272424297811 |
| 2024-10-31 | price per share | 4.9489 USD | Fidelity Advisor Health Care Fund | VERIFIED | valUSD 1587469.74 / balance 320769.0 [unspecified] | 000175272424297782 |
| 2024-10-31 | price per share | 4.9489 USD | Fidelity Advisor Biotechnology Fund | VERIFIED | valUSD 652781.35 / balance 131903.0 [unspecified] | 000175272424297857 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price.